Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE ® in 30 seconds using Halozyme's proprietary high-volume ...

Current quarter guidance for 2026 total revenue of $1.71 billion to $1.81 billion and non-GAAP diluted EPS of $7.75 to $8.25 marks a substantial increase from the previous quarter's guidance of $1.3 ...

TOKYO, Feb 16, 2024 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained ...

WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) accepted the supplemental new drug ...

Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE ® in 30 seconds using Halozyme's proprietary high-volume ...

Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE ® in 30 seconds using Halozyme's proprietary high-volume ...

The Prefilled Auto Injectors Market is poised for robust expansion driven by escalating incidence of chronic conditions, heightened demand for self-administration therapeutics, and intensifying ...